NCT05563558View on ClinicalTrials.gov

Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 5, 2023

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2026

Conditions
Prostate Cancer Metastatic
Interventions
DRUG

Pembrolizumab

Included in arm/group description

DRUG

Carboplatin

Included in arm/group description

DRUG

Cabazitaxel

Included in arm/group description

Trial Locations (1)

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

Sponsors

Lead Sponsor

Fundacion Oncosur
All Listed Sponsors
lead

Fundacion Oncosur

NETWORK

NCT05563558 - Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) | Biotech Hunter | Biotech Hunter